CLINICAL MASKS OF AMYLOIDOSIS WITH THE HEART INVOLVEMENT: MODERN DIAGNOSTIC ISSUES

In amyloidosis AL-type the heart involvement is most common; this type is specific with predecessor proteins of light immunoglobulin chains, transthyretin (TTR), mutant and wild (senile) types. Most common clinical form is restriction cardiomyopathy.

Aim. To assess the recent specifics of diagnostics, due to broader abilities of novel methods.

Material and methods. Five 40-79-year old patients with various morpho￾functional variants of heart involvement and typical ECG signs (low QRS voltage, QS, non-sufficient R increase, absence of left ventricle (LV) hypertrophy signs) to verify the suspected amyloidosis, underwent EchoCG, immunohistochemistry of blood and urine for light chains of immunoglobulines, biopsy of subcutaneous fat and mucose of the gum/gut; MDCT of the heart (n=3), MRI (n=1), scintigraphy with 99Tc-pyrophosphate with assessment in 1 hour after indicator injection (n=1), endomyocardial biopsy (n=2), titer of anticardial antibodies assessment (n=2), DNA-diagnostics (n=1).

Results. The diagnosis of amyloidosis was confirmed in all cases. Its morpho-functional types were RSMP with LV hypertrophy, hypertrophic cardiomyopathy (HCMP) with no restriction but progressing fall of ejection fraction (EF), dilation cardiomyopathy (DCMP), severe hypertrophy with low EF, minimal hypertrophy with no restriction and systolic dysfunction. There was AL-type diagnosed (n=2, one case with myopathy mimicking “dermatomyositis”), mutant TTR (n=1, novel mutation Thr40Asn) and wild TTR (n=2) types. The leading clinical signs were biventricular heart failure and atrial rhythm disorders: sustained atrial fibrillation in 3 patients (in one, before amyloidosis verification, the RF-modification was done as “labyrinth” surgery, isthmus block with no established efficacy) and frequent supraventricular extrasystoly in one another. To the patient with mutant ATTR the ICD was implanted with further replacement by CRT-D, and increase of EF from 24% to 31% was achieved (patient is followed-up for 8 years). As the morphological equivalent of severe systolic dysfunction in this patient the amyloid deposition in myocardial arteries could be suspected. MDCT revealed typical subendocardial delayed deposition in 2 from 3 patients, in one case there was also diffuse deposition of 99Tc-pyrophosphate in myocardium. Antibodies to the nuclei of cardiomyocytes (specific ANF) was found in a female patient with AL-type and DCMP, which made not to rule out myocarditis.

Conclusion. Cardiac amyloidosis might present as any structural and functional variant of cardiomyopathy, including DCMP. The most specific is diffuse hypertrophy with restriction and EF decrease, but with no LV dilation. Early fall of contractility, ischemia symptoms and LV dilation might be the result of amyloid lesion of small arteries. In the presence of any systemic presentations together with “HCMP”, “RCMP”, “DCMP” there must be amyloidosis ruled out. Myocardial scintigraphy with 99Tc-pyrophosphate is a method of use for the diagnosis of ATTR; MDCT of the heart — for any type of amyloidosis. Cardiac amyloidosis might be followed by significant type of the titer of specific ANF (secondary reaction or concomitance with myocarditis?).

1. Библиография.

2. Zhdanova EA, Rameev VV, Moiseev SV et al. Cardiac amyloidosis. Clinical Pharmacology & Therapeutics, 2011, 20(5): 44-50. Russian. [Е.А.Жданова, В.В.Рамеев, С.В.Моисеев и др. Амилоидоз сердца. Клиническая фармакология и терапия, 2011, 20(5): 44-50].

3. García-Pavía P, Tomé-Esteban MT, Rapezzi C. [Amyloidosis. Also a heart disease]. [Article in Spanish]. Rev Esp Cardiol. 2011; 64(9):797-808. doi: 10.1016/j.recesp.2011.05.003.

4. Philippakis AA, Falk RH. Cardiac amyloidosis mimicking hypertrophic cardiomyopathy with obstruction: treatment with disopyramide. Circulation. 2012; 125(14):1821-4. doi: 10.1161/CIRCULATIONAHA.111.064246.

5. Helder MR, Schaff HV, Nishimura RA et al. Impact of incidental amyloidosis on the prognosis of patients with hypertrophic cardiomyopathy undergoing septal myectomy for left ventricular outflow tract obstruction. Am J Cardiol. 2014 Nov 1;114(9):1396-9. doi: 10.1016/j.amjcard.2014.07.058. Epub 2014 Aug 12.

6. Moore S , Symmons DP , DuPlessis D , Chinoy H. Amyloid myopathy masquerading as polymyositis. Clin Exp Rheumatol. 2015; 33(4):590-1.

7. Das A, Mahadevan A, Kishore A, Shankar SK. A case of amyloid myopathy masquerading as inflammatory myopathy. Neurol India. 2010;58(2):325-6. doi: 10.4103/0028-3886.63781.

8. Muchtar E, Derudas D, Mauermann M et al. Systemic Immunoglobulin Light Chain Amyloidosis-Associated Myopathy: Presentation, Diagnostic Pitfalls, and Outcome. Mayo Clin Proc. 2016 Oct;91(10):1354-1361. doi: 10.1016/j.mayocp.2016.06.027.

9. Shimada S, Maekura S, Ino H et al. Unusual Case of Cardiac Amyloidosis Preceded by a Twenty-year History of Dilated Cardiomyopathy and Heart Failure. Intern Med. 2016;55(9):1109-15. doi: 10.2169/internalmedicine.55.5835.

10. Yoshita M, Ishida C, Yanase D, Yamada M. Immunoglobulin light-chain (AL) amyloidosis with myasthenic symptoms and echocardiographic features of dilated cardiomyopathy. Intern Med. 2006;45(3):159-62.

11. Clemmensen TS, Mølgaard H, Andersen NF et al. A rare presentation of cardiac amyloid deposits isolated to intramural vessels. Echocardiography. 2016 Nov;33(11):1777-1780. doi: 10.1111/echo.13365

12. Kristen AV, Ehlermann P, Helmke B et al. Transthyretin valine-94-alanine, a novel variant associated with late-onset systemic amyloidosis with cardiac involvement. Amyloid. 2007;14(4):283-7.

13. Deux JF, Mihalache CI, Legou F et al. Noninvasive detection of cardiac amyloidosis using delayed enhanced MDCT: a pilot study. Eur Radiol. 2015; 25(8):2291-7. doi: 10.1007/s00330-015-3642-2.

14. Treibel TA, Fontana M, Gilbertson JA et al. Occult Transthyretin Cardiac Amyloid in Severe Calcific Aortic Stenosis: Prevalence and Prognosis in Patients Undergoing Surgical Aortic Valve Replacement. Circ Cardiovasc Imaging. 2016, 9(8). pii: e005066. doi: 10.1161/CIRCIMAGING.116.005066.

15. Longhi S, Lorenzini M, Gagliardi C et al. Coexistence of Degenerative Aortic Stenosis and Wild-Type Transthyretin-Related Cardiac Amyloidosis. JACC Cardiovasc Imaging. 2016; 9(3):325-7. doi: 10.1016/j.jcmg.2015.04.012.

16. Perugini E, Guidalotti PL, Salvi F et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol. 2005; 46(6):1076-84. DOI:10.1016/j.jacc.2005.05.073

17. González-López E, Gallego-Delgado M, Guzzo-Merello G et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J. 2015; 36(38):2585-94. doi: 10.1093/eurheartj/ehv338.

18. Bennani Smires Y, Victor G, Ribes D et al. Pilot study for left ventricular imaging phenotype of patients over 65 years old with heart failure and preserved ejection fraction: the high prevalence of amyloid cardiomyopathy. Int J Cardiovasc Imaging. 2016; 32(9):1403-1413.

19. Castano A, Haq M, Narotsky DL et al. Multicenter Study of Planar Technetium 99m Pyrophosphate Cardiac Imaging: Predicting Survival for Patients With ATTR Cardiac Amyloidosis. JAMA Cardiol. 2016; 1(8):880-889. doi: 10.1001/jamacardio.2016.2839.

20. Gillmore JD, Maurer MS, Falk RH et al. Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. Circulation. 2016; 133(24):2404-12. doi: 10.1161/CIRCULATIONAHA.116.021612.

21. Siegismund CS, Lassner D, Kuehl U et al. Inflammation in cardiac amyloidosis correlates with poor prognosis. European Heart Journal, 2016, 37 (Abstract Supplement): 366

22. Tebbe U, Bramlage K, John Fet al. Endomyocardial biopsy in patients with cardiomyopathy of unknown origin: does specialized center experience apply to a tertiary care hospital? BMC Res Notes. 2016; 9(1):459.

23. Rao RR, Yong WC, Wasko MC. Systemic Light Chain Amyloidosis Mimicking Rheumatic Disorders. Case Rep Med. 2016;2016:7649510. doi: 10.1155/2016/7649510.

24. Tan NY, Mohsin Y, Hodge DO et al. Catheter Ablation for Atrial Arrhythmias in Patients With Cardiac Amyloidosis. J Cardiovasc Electrophysiol. 2016; 27(10):1167-1173. doi: 10.1111/jce.13046.

25. Mlcochova H, Saliba W, Burkhardt DJ et al. Catheter ablation of ventricular fibrillation storm in patients with infiltrative amyloidosis of the heart. J Cardiovasc Electrophysiol. 2006; 17(4):426-30.

26. Longhi S, Quarta CC, Milandri A et al. Atrial fibrillation in amyloidotic cardiomyopathy: prevalence, incidence, risk factors and prognostic role. Amyloid. 2015;22(3):147-55. doi: 10.3109/13506129.2015.1028616.

27. Hamon D, Algalarrondo V, Gandjbakhch E et al. Outcome and incidence of appropriate implantable cardioverter-defibrillator therapy in patients with cardiac amyloidosis. Int J Cardiol. 2016;222:562-8. doi: 10.1016/j.ijcard.2016.07.254.

28. Zizek D, Cvijić M, Zupan I. Cardiac resynchronization therapy in a patient with amyloid cardiomyopathy. Acta Cardiol. 2013; 68(3):335-7.

29. Rapezzi C, Merlini G, Quarta CC et al. Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation. 2009;120(13):1203-12. doi: 10.1161/CIRCULATIONAHA.108.843334.

30. Badar T, Cornelison AM, Shah ND et al. Outcome of patients with systemic light chain amyloidosis with concurrent renal and cardiac involvement. Eur J Haematol. 2016; 97(4):342-7. doi: 10.1111/ejh.12736.

31. Cortese A, Vita G, Luigetti M et al. Monitoring effectiveness and safety of Tafamidis in transthyretin amyloidosis in Italy: a longitudinal multicenter study in a non-endemic area. J Neurol. 2016; 263(5):916-24. doi: 10.1007/s00415-016-8064-9.

32. Maurer MS, Grogan DR, Judge DP et al. Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes. Circ Heart Fail. 2015; 8(3):519-26. doi: 10.1161/CIRCHEARTFAILURE.113.000890.

33. Cho Y, Baranczak A, Helmke S et al. Personalized medicine approach for optimizing the dose of tafamidis to potentially ameliorate wild-type transthyretin amyloidosis (cardiomyopathy). Amyloid. 2015;22(3):175-80. doi: 10.3109/13506129.2015.1063485